Transcriptional analysis of doxorubicin-induced cardiotoxicity

Xiaoming Yi, Raffi Bekeredjian, Nicholas Defilippis, Zakir Siddiquee, Eduardo Fernandez, Ralph V. Shohet

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Doxorubicin is an effective chemotherapeutic agent against a broad range of tumors. However, a threshold dose of doxorubicin causes an unacceptably high incidence of heart failure and limits its clinical utility. We have established two models of doxorubicin cardiotoxicity in mice: 1) in an acute model, mice are treated with 15 mg/kg of doxorubicin once; and 2) in a chronic model, they receive 3 mg/kg weekly for 12 wk. Using echocardiography, we have monitored left ventricular function during treatment in the chronic model and seen the expected development of dilated cardiomyopathy. Treated mice showed histological abnormalities similar to those seen in patients with doxorubicin cardiomyopathy. To investigate transcriptional regulation in these models, we used a muscle-specific cDNA microarray. We have identified genes that respond to doxorubicin exposure in both models and confirmed these results using real-time PCR. In the acute model, a set of genes is regulated early and rapidly returns to baseline levels, consistent with the half-life of doxorubicin. In the chronic model, which mimics the clinical situation much more closely, we identified dysregulated genes that implicate specific mechanisms of cardiac toxicity. These include STARS, a hypertrophy-responsive gene; SNF1-kinase, a potential modulator of ATP levels; and AXUD1, a downstream target of the proapoptotic regulator AXIN1.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume290
Issue number3
DOIs
StatePublished - Mar 1 2006
Externally publishedYes

Fingerprint

Doxorubicin
Genes
Dilated Cardiomyopathy
Cardiotoxicity
Oligonucleotide Array Sequence Analysis
Cardiomyopathies
Left Ventricular Function
Hypertrophy
Half-Life
Echocardiography
Real-Time Polymerase Chain Reaction
Phosphotransferases
Heart Failure
Adenosine Triphosphate
Muscles
Incidence
Neoplasms

Keywords

  • Adriamycin
  • Dilated cardiomyopathy
  • Microarray

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Transcriptional analysis of doxorubicin-induced cardiotoxicity. / Yi, Xiaoming; Bekeredjian, Raffi; Defilippis, Nicholas; Siddiquee, Zakir; Fernandez, Eduardo; Shohet, Ralph V.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 290, No. 3, 01.03.2006.

Research output: Contribution to journalArticle

Yi, Xiaoming ; Bekeredjian, Raffi ; Defilippis, Nicholas ; Siddiquee, Zakir ; Fernandez, Eduardo ; Shohet, Ralph V. / Transcriptional analysis of doxorubicin-induced cardiotoxicity. In: American Journal of Physiology - Heart and Circulatory Physiology. 2006 ; Vol. 290, No. 3.
@article{26c208671a4747ada57b91bb09f1a273,
title = "Transcriptional analysis of doxorubicin-induced cardiotoxicity",
abstract = "Doxorubicin is an effective chemotherapeutic agent against a broad range of tumors. However, a threshold dose of doxorubicin causes an unacceptably high incidence of heart failure and limits its clinical utility. We have established two models of doxorubicin cardiotoxicity in mice: 1) in an acute model, mice are treated with 15 mg/kg of doxorubicin once; and 2) in a chronic model, they receive 3 mg/kg weekly for 12 wk. Using echocardiography, we have monitored left ventricular function during treatment in the chronic model and seen the expected development of dilated cardiomyopathy. Treated mice showed histological abnormalities similar to those seen in patients with doxorubicin cardiomyopathy. To investigate transcriptional regulation in these models, we used a muscle-specific cDNA microarray. We have identified genes that respond to doxorubicin exposure in both models and confirmed these results using real-time PCR. In the acute model, a set of genes is regulated early and rapidly returns to baseline levels, consistent with the half-life of doxorubicin. In the chronic model, which mimics the clinical situation much more closely, we identified dysregulated genes that implicate specific mechanisms of cardiac toxicity. These include STARS, a hypertrophy-responsive gene; SNF1-kinase, a potential modulator of ATP levels; and AXUD1, a downstream target of the proapoptotic regulator AXIN1.",
keywords = "Adriamycin, Dilated cardiomyopathy, Microarray",
author = "Xiaoming Yi and Raffi Bekeredjian and Nicholas Defilippis and Zakir Siddiquee and Eduardo Fernandez and Shohet, {Ralph V.}",
year = "2006",
month = "3",
day = "1",
doi = "10.1152/ajpheart.00832.2005",
language = "English (US)",
volume = "290",
journal = "American Journal of Physiology - Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - Transcriptional analysis of doxorubicin-induced cardiotoxicity

AU - Yi, Xiaoming

AU - Bekeredjian, Raffi

AU - Defilippis, Nicholas

AU - Siddiquee, Zakir

AU - Fernandez, Eduardo

AU - Shohet, Ralph V.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Doxorubicin is an effective chemotherapeutic agent against a broad range of tumors. However, a threshold dose of doxorubicin causes an unacceptably high incidence of heart failure and limits its clinical utility. We have established two models of doxorubicin cardiotoxicity in mice: 1) in an acute model, mice are treated with 15 mg/kg of doxorubicin once; and 2) in a chronic model, they receive 3 mg/kg weekly for 12 wk. Using echocardiography, we have monitored left ventricular function during treatment in the chronic model and seen the expected development of dilated cardiomyopathy. Treated mice showed histological abnormalities similar to those seen in patients with doxorubicin cardiomyopathy. To investigate transcriptional regulation in these models, we used a muscle-specific cDNA microarray. We have identified genes that respond to doxorubicin exposure in both models and confirmed these results using real-time PCR. In the acute model, a set of genes is regulated early and rapidly returns to baseline levels, consistent with the half-life of doxorubicin. In the chronic model, which mimics the clinical situation much more closely, we identified dysregulated genes that implicate specific mechanisms of cardiac toxicity. These include STARS, a hypertrophy-responsive gene; SNF1-kinase, a potential modulator of ATP levels; and AXUD1, a downstream target of the proapoptotic regulator AXIN1.

AB - Doxorubicin is an effective chemotherapeutic agent against a broad range of tumors. However, a threshold dose of doxorubicin causes an unacceptably high incidence of heart failure and limits its clinical utility. We have established two models of doxorubicin cardiotoxicity in mice: 1) in an acute model, mice are treated with 15 mg/kg of doxorubicin once; and 2) in a chronic model, they receive 3 mg/kg weekly for 12 wk. Using echocardiography, we have monitored left ventricular function during treatment in the chronic model and seen the expected development of dilated cardiomyopathy. Treated mice showed histological abnormalities similar to those seen in patients with doxorubicin cardiomyopathy. To investigate transcriptional regulation in these models, we used a muscle-specific cDNA microarray. We have identified genes that respond to doxorubicin exposure in both models and confirmed these results using real-time PCR. In the acute model, a set of genes is regulated early and rapidly returns to baseline levels, consistent with the half-life of doxorubicin. In the chronic model, which mimics the clinical situation much more closely, we identified dysregulated genes that implicate specific mechanisms of cardiac toxicity. These include STARS, a hypertrophy-responsive gene; SNF1-kinase, a potential modulator of ATP levels; and AXUD1, a downstream target of the proapoptotic regulator AXIN1.

KW - Adriamycin

KW - Dilated cardiomyopathy

KW - Microarray

UR - http://www.scopus.com/inward/record.url?scp=33645738498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645738498&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00832.2005

DO - 10.1152/ajpheart.00832.2005

M3 - Article

C2 - 16243910

AN - SCOPUS:33645738498

VL - 290

JO - American Journal of Physiology - Endocrinology and Metabolism

JF - American Journal of Physiology - Endocrinology and Metabolism

SN - 0193-1849

IS - 3

ER -